Evidence map›Paper›PMID 42667367›Full record

ArticleWorld journal of urology2026

Using human proteomic and lipidomic to exploration drug target of bladder cancer.

Qian Cao, Hongyan Liu, Yangyang Xu, Youzhi Wang, Li An, Junbo Li, Haitao Ren, Diansheng Zhou, Jiaming Liang, Zhaokai Guan and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Qian Cao *Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Hongyan Liu *Department of Family Planning, The Second Hospital of Tianjin Medical University, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Yangyang Xu *Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Youzhi Wang *Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Li An *Department of Respiratory Medicine, Chinese PLA General Hospital, Beijing, China.
Junbo Li *Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Haitao RenDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Diansheng ZhouDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Jiaming LiangDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Zhaokai GuanDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Weiwei WangDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Changli WuDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Yang YangDepartment of Family Planning, The Second Hospital of Tianjin Medical University, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. yy@tmu.edu.cn.
Jianmei WangDepartment of Family Planning, The Second Hospital of Tianjin Medical University, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. wangjianmei@tmu.edu.cn.
Ning JiangDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China. jiangning@tmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe goal of this study is to explore the genetic predictive associations between plasma proteomics and bladder cancer using the Mendelian randomization (MR) method, and to investigate whether plasma lipidomics characteristics mediate these associations. MATERIALS AND

methodsThe genome-wide association study (GWAS) data for plasma proteins from deCODE Genetics included 4,907 aptamers for plasma proteins in 35,559 Icelandic individuals. Lipidomic GWAS data of 179 traits (GCST90277238-GCST90277416) were extracted from the GWAS Catalog, and bladder cancer GWAS summary statistics were sourced from FinnGen R8 (2,380 cases and 259,583 controls). Two-sample MR evaluated the causal links between genetically predicted plasma proteins and bladder cancer risk; mediation MR further examined mediating roles of lipidomic. Primary causal analyses adopted the MR Wald ratio and inverse variance-weighted approaches. Heterogeneity was tested by the Cochrane Q test, horizontal pleiotropy by MR-Egger intercept test, and leave-one-out analysis was used for sensitivity assessment. RESULTS AND LIMITATIONS: Our findings suggest that genetically predicted levels of 29 proteins may be associated with the risk of bladder cancer. Among these, 17 proteins showed inverse associations with bladder cancer risk, while 12 proteins showed positive associations. A negative mediation proportion indicates that the estimated direction of the indirect effect is opposite to that of the total effect. For example, the mediation proportion of -56% for ETFA suggests that the estimated indirect effect through GCST90277318 is in the opposite direction to the overall association observed between genetically predicted ETFA levels and bladder cancer risk. When ADGRF1 was considered as the exposure and GCST90277318 as the mediator, the estimated proportion mediated was 25%. For NDUFB4 and GCST90277318, the estimated proportion mediated was 20%. For ETFA and GCST90277318, the estimated proportion mediated was -56%, whereas the estimated mediation proportions for most other protein-lipid pairs were approximately 10%.These results reflect putative causal estimates derived from genetic instruments rather than direct causal effects.The findings should be interpreted in light of several limitations, including the use of summary-level data, predominantly European ancestry populations, and the potential bias from lifestyle and clinical confounders,and the need for experimental validation of the identified associations and proposed biological mechanisms.

conclusionsThis MR study revealed suggestive genetically predicted associations between 29 plasma proteins and bladder cancer risk, and implied that plasma lipidomic traits may partially mediate a subset of these relationships. These observations may shed light on potential molecular mechanisms relevant to bladder cancer and offer candidate proteins for further functional research and therapeutic target verification.

Indexed as

Blood ProteinsLipidomicsProteomicsUrinary Bladder NeoplasmsGenome-Wide Association StudyHumansMendelian Randomization AnalysisBlood ProteinsBladder cancerMediation Mendelian randomizationPlasma lipidomicPlasma proteomicTwo-sample Mendelian randomization

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.